Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis by unknown
REVIEW ARTICLE
Effect of Fingolimod on Brain Volume Loss in Patients
with Multiple Sclerosis
Nicola De Stefano1 • Diego G. Silva2 • Michael H. Barnett3
Published online: 28 February 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract Brain atrophy occurs at a faster rate in patients
with multiple sclerosis (MS) than in healthy individuals. In
three randomized, controlled, phase III trials, fingolimod
reduced the annual rate of brain volume loss (BVL) in
patients with relapsing MS (RMS) by approximately one-
third relative to that in individuals receiving placebo or
intramuscular interferon beta-1a. Analysis of brain volume
changes during study extensions has shown that this
reduced rate of BVL is sustained in patients with RMS
receiving fingolimod continuously. Subgroup analyses of
the core phase III and extension studies have shown that
reductions in the rate of BVL are observed irrespective of
levels of inflammatory lesion activity seen by magnetic
resonance imaging at baseline and on study; levels of
disability at baseline; and treatment history. The rate of
BVL in these studies was predicted independently by T2
lesion and gadolinium-enhancing lesion burdens at base-
line, and correlations observed between BVL and
increasing levels of disability strengthened over time. In
another phase III trial in patients with primary progressive
MS (PPMS), fingolimod did not reduce BVL overall rela-
tive to placebo; however, consistent with findings in RMS,
there was a treatment effect on BVL in patients with PPMS
with gadolinium-enhancing lesion activity at baseline. The
association between treatment effects on BVL and future
accumulation of disability argues in favor of measuring
BVL on a more routine basis and with a more structured
approach than is generally the case in clinical practice.
Despite several practical obstacles, progress is being made
in achieving this goal.
Key Points
Fingolimod reduces the rate of brain volume loss in
patients with relapsing multiple sclerosis (RMS), and
this effect is independent of disease status and
previous treatment history.
Brain volume is clinically relevant in RMS because
it tracks disease progression, and the rate of brain
volume loss predicts long-term disability.
Routine measurement of brain volume in RMS could
be valuable in informing treatment decisions.
Although reliable, longitudinal measurement of brain
volume to determine rate of loss is difficult in routine
clinical practice; developments in magnetic
resonance imaging analysis are beginning to address
the challenges faced.
1 Introduction
Brain atrophy is a characteristic feature of multiple scle-
rosis (MS) that occurs throughout the disease course [1–3].
On magnetic resonance imaging (MRI), brain volume loss
(BVL) between two or more time points can be accurately
determined by co-registration-based analysis, using algo-
rithms such as ‘Structural Image Evaluation, using Nor-
malization, of Atrophy’ (SIENA) [1, 4–6]. Patients with
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MS lose brain volume (BV) at a considerably faster rate
than age-matched individuals who do not have MS
[1, 3, 7, 8], and data from studies using the SIENA method
have shown that the annual percentage BV change (PBVC)
among healthy adults is approximately -0.1 to -0.3%
[8–11], compared with -0.4 to -1.0% in patients with MS
[2, 3, 7, 8, 11]. Furthermore, a threshold annual rate of
-0.4% can distinguish healthy individuals from patients
with MS, with a specificity of 80% and a sensitivity of 65%
[8]. BVL has been shown to correlate with and predict
disability [1, 12–15], representing a relevant measure of
central nervous system damage associated with MS disease
progression. As such, BVL is a useful outcome measure for
evaluating the relative efficacy of MS therapies [16–18].
Fingolimod (Gilenya, FTY720; Novartis Pharma AG,
Basel, Switzerland) is a sphingosine 1-phosphate receptor
modulator and was the first oral therapy (0.5 mg once
daily) available for patients with relapsing MS (RMS) [19].
In three randomized, double-blind, controlled, phase III
studies of fingolimod in patients with RMS (FREEDOMS
[FTY720 Research Evaluating Effects of Daily Oral ther-
apy in Multiple Sclerosis] [20], FREEDOMS II [21], and
TRANSFORMS [Trial Assessing injectable interferon vs
FTY720 Oral in Relapsing-remitting Multiple Sclerosis]
[22]), consistent reductions in the rate of BVL were
observed with fingolimod compared with placebo or
intramuscular interferon beta-1a (IFNb-1a IM) [20–22].
Reductions in the rate of BVL have also been reported for a
number of MS disease-modifying therapies [11]. Treatment
with IFNb or glatiramer acetate reduced the rate of BVL
compared with no treatment in patients with relapsing–
remitting MS (RRMS), and over 5 years BVL was lower
with glatiramer acetate than with either low-dose or high-
dose IFNb [23]. More recently, a retrospective analysis of
natalizumab therapy in patients with MS showed that
although significant BVL occurred during the first year of
therapy, the rate was reduced in the second and third years
[24], and compared with subcutaneous IFNb, alemtuzumab
slowed the rate of BVL in patients with RRMS over 2 years
in the two CARE-MS (Comparison of Alemtuzumab and
Rebif Efficacy in Multiple Sclerosis) trials [25].
The precise mechanism by which fingolimod reduces
the rate of BVL in patients with RMS has not been fully
elucidated, but may be a consequence of direct anti-in-
flammatory effects and of indirect effects on neurodegen-
erative processes triggered by inflammation [26]. Data
reviewed here will focus on the fingolimod 0.5-mg dose,
although significant effects on BVL were also seen among
patients receiving the 1.25-mg dose in clinical trials. A
substantial proportion of participants in FREEDOMS,
FREEDOMS II and TRANSFORMS continued to receive
fingolimod in the respective extensions to these studies
[27–29], and most continue to be followed up under the
umbrella of the LONGTERMS study, a single-arm, open-
label extension following up patients with relapsing MS
receiving fingolimod, who were enrolled in the various
phase II, III and IIIb fingolimod trials [30]. The effect of
fingolimod in patients with primary progressive MS
(PPMS) has also been evaluated in the phase III placebo-
controlled INFORMS trial (Oral Fingolimod in Primary
Progressive Multiple Sclerosis) [31].
In this review, we will focus on the effects of fingolimod
in reducing the rate of BVL in these studies, and in various
patient subgroups, based on demographic, clinical, or MRI
characteristics at baseline. We will also discuss the clinical
significance of, and factors that may be predictive of,
increased rates of BVL in patients with MS. Finally, we
will summarize guideline recommendations and challenges
for the routine assessment of changes in BV in clinical
practice.
2 Effect of Fingolimod on BVL in Patients
with RMS
2.1 Reductions in BVL with Fingolimod: Evidence
from Randomized, Double-Blind, Controlled
Phase III Studies
The three phase III studies of fingolimod in patients with
RMS were FREEDOMS [20], FREEDOMS II [21] and
TRANSFORMS [22] (see Table 1 for an overview of the
study designs). Across these trials, BVL was measured by
estimating PBVC using SIENA. Reductions in BVL with
fingolimod were rapid (detected at 6 months) compared
with placebo in the FREEDOMS trials [20, 21], and were
demonstrated consistently over 2 years in these trials, and
over 1 year compared with IFNb-1a IM in TRANSFORMS
[22].
2.1.1 Fingolimod versus Placebo: FREEDOMS
and FREEDOMS II
The FREEDOMS [20] and FREEDOMS II [21] trials were
24-month, multicenter, randomized, double-blind, placebo-
controlled, parallel-group studies that compared the effi-
cacy of oral fingolimod (1.25 and 0.5 mg/day) with pla-
cebo in patients with RMS (Table 1). In FREEDOMS
(N = 1272), both doses of fingolimod significantly reduced
the rate of BVL over 2 years, compared with placebo. The
reduction in mean rate of BVL was 35% with fingolimod
compared with placebo (p\ 0.001) after 24 months of
treatment. Of note, significant reductions in the rate of
BVL compared with placebo were detected as early as
6 months in both treatment groups (Table 2) [20]. Similar
effects were seen in the FREEDOMS II study (N = 1083);











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































292 N. De Stefano et al.
after 24 months of treatment, the reduction in mean rate of
BVL was 33% with fingolimod compared with placebo
(p\ 0.001), and this effect on BVL was detected as early
as 6 months (Table 2) [21].
2.1.2 Fingolimod versus IFNb-1a IM: TRANSFORMS
TRANSFORMS (N = 1292) was a 12-month, multicenter,
randomized, double-blind, active-controlled, double-
dummy, parallel-group study that compared the efficacy of
oral fingolimod (1.25 and 0.5 mg/day) with IFNb-1a IM
(30 lg/week) in patients with RMS (Table 1) [22]. In this
study, both doses of fingolimod significantly reduced the
rate of BVL compared with IFNb-1a IM; after 12 months
of treatment, the reduction in mean rate of BVL was 32%
with fingolimod 0.5 mg compared with IFNb-1a IM
(p\ 0.001; Table 2) [22].
2.1.3 Post Hoc Analyses of FREEDOMS, FREEDOMS II
and TRANSFORMS
An analysis of data pooled from FREEDOMS, FREE-
DOMS II, TRANSFORMS, and their extensions was
conducted to determine the delay in BVL following con-
tinuous treatment with fingolimod relative to that following
treatment with placebo or IFNb-1a IM. The analysis cal-
culated the additional time required for fingolimod-treated
patients to reach the levels of BVL observed in the control
groups at the end of the core study. It showed that patients
receiving continuous fingolimod took 56–61% longer than
those receiving placebo, and 46% longer than those
receiving IFNb-1a IM, to sustain comparable levels of
BVL [32].
2.2 Sustained Effects of Fingolimod in Reducing
BVL
The long-term effects of fingolimod on BVL have been
evaluated in the FREEDOMS, FREEDOMS II, and
TRANSFORMS extensions [27–29] (see Table 1 for an
overview of extension study designs). Patients who com-
pleted each of the three core phase III studies were eligible
to enter the respective extension study, in which they either
continued to receive fingolimod (continuous groups) or
were switched from placebo (FREEDOMS and FREE-
DOMS II) or from IFNb-1a IM (TRANSFORMS) to
receive fingolimod (switch groups). Patients in the switch
groups were randomized 1:1 to receive either fingolimod
1.25 mg or fingolimod 0.5 mg [27–29], although all
patients receiving fingolimod were later de-escalated to the
0.5 mg dose. The beneficial effects of fingolimod on BVL
that were observed in the FREEDOMS, FREEDOMS II,
and TRANSFORMS core studies were maintained among
patients who continued to receive fingolimod in the
respective extension studies. Furthermore, patients who
switched to fingolimod during the extensions (from either
placebo or IFNb-1a IM in the core studies), benefited from
reduced rates of BVL relative to the rates experienced
during the core studies [27–29].
In the FREEDOMS extension (N = 920), patients who
received continuous fingolimod experienced less overall
BVL at 4 years than patients who were switched from
Table 2 Percentage change in
BV during three pivotal phase
III trials of fingolimod in
patients with RMS
Endpoint Fingolimod 0.5 mg, oral Placebo IFNb-1a IM 30 lg/week
Mean (SD) change in BV from 0 to 6 months, %
FREEDOMS [20] -0.22 (0.81); p = 0.006 -0.34 (0.73)
FREEDOMS II [21] -0.23 (0.87); p = 0.012 -0.38 (0.91)
Mean (SD) change in BV from 0 to 12 months, %
FREEDOMS [20] -0.50 (1.05); p = 0.03 -0.65 (1.05)
FREEDOMS II [21] -0.38 (0.97); p\ 0.001 -0.63 (1.05)
TRANSFORMS [22] -0.31 (0.65); p\ 0.001 -0.45 (0.73)
Mean (SD) change in BV from 12 to 24 months, %
FREEDOMS [20] -0.37 (0.81); p\ 0.001 -0.67 (1.07)
FREEDOMS II [21] -0.49 (0.90); p = 0.013 -0.68 (1.10)
Mean (SD) change in BV from 0 to 24 months, %
FREEDOMS [20] -0.84 (1.31); p\ 0.001 -1.31 (1.50)
FREEDOMS II [21] -0.86 (1.22); p\ 0.001 -1.28 (1.50)
Measured by SIENA
BV brain volume, IFNb-1a interferon beta-1a, IM intramuscular, RMS relapsing multiple sclerosis, SD
standard deviation, SIENA Structural Image Evaluation, using Normalization, of Atrophy
p Values in FREEDOMS and FREEDOMS II are versus placebo; p values in TRANSFORMS are versus
IFNb-1a IM
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placebo to fingolimod. Mean (standard deviation) exposure
to fingolimod was 1394 (208) days in the continuous group
and 669 (206) days in the switch group. From day 0
(FREEDOMS baseline) to end of study (EOS) in the
FREEDOMS extension, the mean rate of BVL was 23%
lower in the continuous fingolimod group (1.7%) than in
the switch group (2.2%; p = 0.0013) (Fig. 1). However,
mean BVL within the group that switched to fingolimod
0.5 mg was 1.42% during months 0–24 and 0.90% during
months 24–48 (p = 0.008). Moreover, during months
24–48, mean rates of BVL in the continuous fingolimod
group and in the switch group were similar (0.78 and
0.90%, respectively). The comparably low rates of BVL
reported across all groups during the extension study are
consistent with the assumption that effects of fingolimod
on BVL are not confined to the first 2 years of treatment
[27]. Similar effects were seen in the FREEDOMS II
extension study (N = 632). From day 0 to EOS, the mean
rate of BVL was 25% lower in the continuous fingolimod
group than in the switch group (p = 0.006 vs switch group)
(Fig. 1). However, from month 24 to EOS, there were no
significant between-group differences in BVL [29].
During the TRANSFORMS extension (N = 1027),
patients in the fingolimod 0.5 mg switch group experienced
pronounced (approximately 50%) and significant reduc-
tions in the rate of BVL compared with the reductions
sustained with IFNb-1a IM during the core study. Mean
BVL was 0.45% in the 12 months before switching and
0.22% in the 12 months after switching (p = 0.006) [28].
This effect was maintained throughout the TRANSFORMS
extension, with patients in the switch groups experiencing a
reduced rate of BVL for up to 4.5 years of treatment. By
the end of the extension, those in the switch group had
‘caught up’ with those receiving fingolimod continuously,
mean BVL from baseline in the two groups being 0.96 and
1.01%, respectively; p = not significant) (Fig. 2) [33].
In the ongoing LONGTERMS trial (N = 2355), an
open-label, single-arm, long-term extension to various
phase II, III and IIIb trials including FREEDOMS,
FREEDOMS II, and TRANSFORMS (Table 1), interim
data demonstrated that low rates of BVL were sustained for
up to 6 years of treatment, although the number of patients
at months 60 and 72 was small (analyses to date have
included only patients randomized initially to receive fin-
golimod 0.5 mg in the two FREEDOMS trials). Impor-
tantly, in terms of reduced levels of BVL, patients who
were randomized to placebo in the core FREEDOMS trials
and then switched to fingolimod in the extension studies
did not recoup the advantages gained by those who
received continuous fingolimod in both the core and
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Fig. 1 Mean percentage change in BV (measured with SIENA) from
day 0 to EOS in FREEDOMS, FREEDOMS II and their extensions
[27, 29]. All p values are versus the respective extension study switch
group. BV brain volume, EOS end of study, SIENA Structural Image
Evaluation, using Normalization, of Atrophy
Continuous fingolimod 




































Fig. 2 Mean percentage change
in BV (measured with SIENA)
from core study baseline in the
continuous and switched groups
of patients participating in
TRANSFORMS and its
extension. In the switched
group, patients were switched
from IFN beta-1a IM to
fingolimod at month 12.
Adapted with permission from
Cohen et al. [33]. BV brain
volume, EOS end of study, IFN




***p\ 0.001 versus switch
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2.3 Patient History and Disease Characteristics Can
Affect BVL, But Do Not Generally Influence
the Effect of Fingolimod on BVL
2.3.1 Inflammatory Disease Activity at Baseline:
Gadolinium-Enhancing Lesions and Relapses
Patient subgroup analyses were performed in the FREE-
DOMS population to determine whether BVL, and the
effect of fingolimod on BVL, were affected by baseline
inflammatory activity, defined as the presence or absence
of gadolinium-enhancing (Gd?) lesions at baseline.
Overall, BVL was greater in patients with Gd? lesions at
baseline than in those without; however, fingolimod sig-
nificantly reduced BVL in both subgroups compared with
placebo (Fig. 4). In the subgroup of patients with Gd?
lesions at baseline, BVL was similar in the fingolimod
0.5 mg and placebo arms at months 6 and 12, but was
significantly lower with fingolimod than with placebo at
month 24 (p = 0.01). Among patients with no Gd? lesions
at baseline, a slower rate of BVL was observed with fin-
golimod than with placebo as early as month 6 (p = 0.01),
and this was maintained at month 24 (p = 0.002). During
months 12–24, fingolimod resulted in significant reductions
in BVL relative to placebo, regardless of Gd? lesion status
at baseline (presence, p\ 0.001; absence, p = 0.002). The
apparent lack of a treatment effect at months 6 and 12 in
the subgroup of patients with Gd? lesions at baseline may
be attributable to accelerated BVL caused by fingolimod
reducing inflammatory activity in these patients (i.e.,
pseudoatrophy). Taken together, the significantly lower
rate of BVL at 6 months in patients with no Gd? lesions
on fingolimod (vs on placebo) and the effect of fingolimod
from month 12 onwards in patients regardless of their Gd?
lesion status at baseline support the hypothesis that
fingolimod has an early and continuous direct beneficial
effect on BVL [35].
A similar subgroup analysis in the TRANSFORMS
population also identified a higher rate of BVL among
patients with, than among those without, Gd? lesions at
baseline. Fingolimod reduced BVL relative to IFNb-1a IM
in both subgroups at 12 months, but this between-group
difference only reached significance in patients who had
Gd? lesions at baseline [36]. The same analysis of
TRANSFORMS also stratified patients by their relapse
activity in the 2 years before enrollment. Fingolimod
reduced BVL compared with IFNb-1a IM in all of the
subgroups analyzed, with larger effect sizes seen among
patients with higher numbers of relapses (two or more
relapses during the 2 years before enrollment), and the
smallest (non-significant) effect size observed in those with
only one relapse in the 2 years before enrollment [36].
2.3.2 Disease Burden at Baseline: T2 Lesions
and Disability
Patient subgroup analyses also examined whether T2 lesion
burden or disability status at baseline influenced the effect
of fingolimod. In FREEDOMS, patients with a total base-
line T2 lesion volume of[3300 mm3 had a faster rate of
BVL than those with a lower T2 lesion burden. Despite this
difference in the rate of BVL, fingolimod significantly
reduced BVL in both higher and lower lesion-burden
subgroups relative to placebo (relative reductions of 34.5%
[p\ 0.001] and of 37.3% [p = 0.02], respectively) [35].
Dichotomization of patients in TRANSFORMS using the
same criteria also identified a higher rate of BVL among
patients with higher T2 lesion volumes. Again, fingolimod
reduced the rate of BVL in both subgroups relative to









































Fig. 3 Mean percentage change
in BV (measured with SIENA)
from baseline (core
FREEDOMS and FREEDOMS
II) in the continuous and
switched groups of patients
participating in the
LONGTERMS extension study
[34]. In the switched groups,
patients were switched from
placebo to fingolimod at month
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reached significance only among those with a higher T2
lesion burden [36].
To examine whether the effect of fingolimod on BVL
was influenced by disability level at baseline, subgroup
analyses were conducted based on patients’ baseline
Expanded Disability Status Scale (EDSS) scores (EDSS
score of 0–3.5 or [3.5). In FREEDOMS, fingolimod
reduced BVL substantially relative to placebo at 2 years in
both subgroups, but the difference between treatments was
not significant among those with more severe disability
(relative BVL reduction: EDSS score B3.5, 32.7%
[p\ 0.001]; EDSS score [3.5, 42.2% [p = 0.10]) [35].
Essentially, the same pattern was seen in TRANSFORMS,
fingolimod being associated with greater reductions in
BVL compared with IFNb-1a IM, although the difference
between treatments was significant in both EDSS sub-
groups (p = 0.043 and p = 0.008, respectively) [36].
2.3.3 Ongoing Disease Activity: Gd? Lesions, New
or Enlarged T2 Lesions and Disability
To determine whether ongoing inflammatory MRI disease
activity influenced the effect of fingolimod on BVL, the
following dichotomous subgroups in TRANSFORMS were
examined: presence/absence of Gd? lesions at baseline;
presence/absence of new disease activity (Gd? lesions and
new or enlarged T2 lesions) at month 12; and presence/
absence of Gd? lesions at baseline and new disease
activity at month 12. There were generally higher rates of
BVL among patients with ongoing inflammatory disease
activity than among those with none, and fingolimod
reduced BVL significantly relative to IFNb-1a IM over
12 months in most subgroups. For fingolimod and IFNb-1a
IM, BVL was 0.40 and 0.52%, respectively, among
patients with new disease activity at month 12 (p = 0.023),
and 0.22 and 0.37% among those with no new disease
activity at month 12 (p = 0.046). Among patients with
Gd? lesions at baseline and new disease activity at month
12, respective BVL was 0.39 and 0.55% (p = 0.012).
However, fingolimod did not exert a significant treatment
effect on BVL among patients with no MRI lesion activity
at baseline or at month 12 (fingolimod 0.19%; IFNb-1a IM
0.26%; p = 0.536) [37].
Building on such investigations of disease activity on
study, an analysis was undertaken to examine a more
comprehensive classification of disease activity than that
based on MRI lesion activity alone. Over 4 years in
FREEDOMS and its extension, effects on BVL were
compared in patients with or without disease activity, based
on the following classification of being disease-free: no
disability progression (defined as an increase in EDSS
score of C1.0 confirmed at 3 months), no confirmed
relapses, no Gd? lesions, and no new or enlarged T2
lesions. Throughout the 4-year study period, patients who
were disease-free experienced less BVL than those with
disease activity (BVL 0–48 months: disease-free 1.36%;
not disease-free 2.08%), and this difference was observed
as early as 12 months (BVL 0–12 months: disease-free
0.17%; not disease-free 0.60%). Regardless of disease-ac-
































































Fig. 4 Mean percentage change in BV (measured with SIENA) from
baseline in the 2-year FREEDOMS trial, in subgroups of patients with
and without gadolinium-enhancing lesions at baseline [35]. BV brain
volume, Gd? gadolinium-enhancing, SIENA Structural Image Eval-
uation, using Normalization, of Atrophy; *p\ 0.05, **p\ 0.01,
***p\ 0.001 versus placebo
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continuously experienced less BVL than those who were
switched from placebo to fingolimod at extension study
entry [38].
2.3.4 Treatment History and Response to Previous
Treatment
As well as considering whether patients’ disease status and
history might influence the effect of fingolimod on BVL,
analyses were undertaken to examine whether patients’
treatment history before receiving fingolimod may be
important. At month 24 in FREEDOMS, fingolimod
reduced BVL by 48.8% in previously treated patients, and
by 24.4% in previously untreated patients relative to those
receiving placebo (p = 0.002 and p = 0.02, respectively)
[35]. At month 12 in TRANSFORMS, fingolimod reduced
BVL relative to IFNb-1a IM in both treatment-naı¨ve
(p = 0.01) and previously treated patients, although the
between-group effect did not reach significance in the latter
subgroup (p = 0.108) [36].
Further analyses then examined patients, either previ-
ously treated or treatment-naı¨ve, who had relatively high
levels of disease activity at enrollment into the phase III
trials, in order to examine BVL outcomes among patients
who were apparently non-responsive to other treatments.
Patients in FREEDOMS and in TRANSFORMS were
stratified into three subgroups, which were categorized
based on the European approval criteria for fingolimod at
the time. Patients in group 1 had had at least as many
relapses in the year before enrollment as in the preceding
year, and those in group 2 had had at least one relapse in
the year before enrollment, and at least either one Gd?
lesion or nine T2 lesions at baseline; patients in both
groups had previously received IFNb therapy before
enrollment. Group 3 comprised treatment-naive patients
who had experienced at least two relapses in the year
before enrollment and had at least one Gd? lesion at
baseline. In groups 1 and 2 in FREEDOMS, the rate of
BVL was reduced with fingolimod by 76–78% relative to
placebo over 24 months (p\ 0.001, both groups), and in
TRANSFORMS, fingolimod reduced BVL over 12 months
in both groups by 40% relative to IFNb-1a (p = 0.006 and
p = 0.016, respectively). A similar, non-significant
reduction (approximately 38%) was observed relative to
IFNb-1a IM among patients in group 3 in TRANSFORMS,
but there was little evidence of a reduction in BVL relative
to placebo in group 3 in FREEDOMS [39]. As patients in
group 3 were treatment-naı¨ve and had inflammatory dis-
ease activity at enrollment, it is likely that BVL measured
in those receiving fingolimod was at least in part
attributable to pseudoatrophy.
Analysis of groups 1 and 2 (defined as above but among
patients receiving any disease-modifying therapy in the
year before enrollment) in a large patient population based
on data pooled from FREEDOMS and FREEDOMS II
identified BVL reductions of 45–50% (p\ 0.001) over
24 months with fingolimod relative to placebo [40].
Analysis of patients from this pooled population, who had
been previously treated with glatiramer acetate and fulfilled
the criteria for categorization in groups 1 and 2, showed
that fingolimod reduced median BVL by 56% over
24 months relative to placebo (0.70 and 1.58%, respec-
tively; p = 0.004) [41].
3 Fingolimod in Primary Progressive MS
3.1 Fingolimod Did Not Reduce BVL
in the Placebo-Controlled Phase III INFORMS
Trial
Approximately 10–15% of patients with MS experience
progressive disability from disease onset, with no, or with
very infrequent relapses (i.e. PPMS) [42, 43]. The
INFORMS trial (N = 970) was a phase III, randomized,
double-blind, placebo-controlled, parallel-group study
designed to assess the efficacy and safety of fingolimod in
patients with PPMS (Table 1) [31]. INFORMS did not
meet its primary efficacy endpoint as there was no signif-
icant difference in the time to 3-month confirmed disability
progression when comparing patients receiving fingolimod
0.5 mg or placebo (hazard ratio 0.95; 95% confidence
intervals 0.80–1.12; p = 0.544). However, although over-
all levels of inflammatory activity in the INFORMS pop-
ulation were low at baseline (13–14% of patients had Gd?
lesions at study entry), fingolimod exerted substantial and
significant effects relative to placebo on the number of new
or enlarged T2 lesions (73% reduction; p\ 0.0001), on the
number of Gd? lesions (78% reduction; p\ 0.0001), and
on the number of new T1 hypointense lesions (62%
reduction; p\ 0.0001) [31].
The between–treatment-group difference in BVL was
non-significant during the study. Mean BVL from baseline
to month 36 was 1.49% for fingolimod 0.5 mg and 1.53%
for placebo (p = 0.673) [31]. Very little information has
been reported on BVL in PPMS. Based on these data,
annual BVL over 3 years in INFORMS was approximately
0.5%, a rate that was lower than anticipated. Previously, a
comparative study of BVL rates across different MS phe-
notypes estimated mean annual BVL in untreated PPMS to
be 0.56% [2]. Post hoc analyses of INFORMS have indi-
cated that BVL on study correlated with disability wors-
ening in patients with PPMS [44], an association that has
also been shown in patients with RMS [45]; and analyses
also revealed that BVL on study, and fingolimod’s treat-
ment effect on BVL in INFORMS, were both dependent on
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the presence of Gd? lesion activity at baseline [44]. In
contrast, the treatment effect of fingolimod on BVL in
RMS is independent of baseline Gd? lesion activity (Sect.
2.3.1). It has been proposed that the nature of neurode-
generation in PPMS and the underlying pathogenesis
causing BVL differ in RMS [46–48], in which the under-
lying pathological mechanisms appear to be influenced by
fingolimod in the absence of inflammatory lesions. How-
ever, in the presence of inflammation, the treatment effect
of fingolimod on BVL in INFORMS was consistent with
the effect seen in patients with RMS [44].
4 Correlates of BV and Its Clinical Relevance
4.1 Baseline Correlates of Baseline BV
A post hoc, exploratory analysis of 3635 patients from
FREEDOMS, FREEDOMS II, TRANSFORMS, and their
extensions, examined whether various demographic,
clinical, and MRI parameters correlated with BV and
BVL (Table 3). The analyses showed that increasing age,
duration of disease, T2 lesion burden, T1-hypointense
lesion burden, and disability level (assessed by EDSS and
Multiple Sclerosis Functional Composite [MSFC] score)
all correlated with reduced normalized BV (NBV) at
baseline (all, p\ 0.001). Thus, older patients with more
advanced disease were likely to have smaller NBV than
younger patients with less advanced disease. These
associations might be anticipated, given that the measures
are indicative of disease severity, but the measures were
also found to contribute independently to BVL after
adjusting for age, suggesting that BVL reflects not only
disease severity, but also disease progression [45]. A
separate exploratory analysis of data from TRANS-
FORMS (N = 1280) also found that several demographic
and disease characteristics correlated with baseline NBV.
These were baseline T1-hypointense lesion volume
(p\ 0.001), treatment for MS before enrollment
(p = 0.016), baseline T2 lesion volume (p\ 0.001), age
(p\ 0.001), duration of MS (p = 0.012), and the inter-
action between baseline T1 hypointense lesion volume
and T2 lesion volume (p\ 0.001) [49].
4.2 Baseline Predictors of On-Study BVL
In the first of the two analyses discussed in the previous
section, demographic variables such as age and sex did not
predict on-study BVL, whereas baseline clinical and MRI
characteristics such as disability level (MSFC score), dis-
ease burden (baseline T2 and T1-hypointense lesion vol-
umes), inflammatory lesion activity (Gd? lesion count),
and NBV all significantly predicted risk of BVL over the 1-
to 2-year study period (all p\ 0.05). The strongest indi-
vidual predictors were baseline T2 lesion volume and Gd?
lesion count. Notably, T2 lesion volume was a better pre-
dictor of BVL than was T1-hypointense lesion volume,
perhaps indicating that T2 lesion volume captures evidence
of current lesion activity, and hence is more likely to reflect
future lesion activity than is T1-hypointense lesion volume
[45]. In the post hoc analysis of the TRANSFORMS data
set, baseline Gd? lesion count, total T2 lesion volume,
disease duration, and NBV were all significant predictors
of BVL over the 1-year study period (all p\ 0.05), and
among these, baseline Gd? lesion count was the strongest
predictor [49].
4.3 Longitudinal Factors that Correlate with BVL
on Study
During FREEDOMS, FREEDOMS II, TRANSFORMS,
and their extensions, the greatest levels of BVL correlated
with the most pronounced MRI and clinical activity. For
example, the number of confirmed relapses, the number of
new/enlarged T2 lesions, and the cumulative number of
Gd? lesions all correlated strongly with the observed BVL
[45]. After 1 year, there was also a significant correlation
between the extent of BVL and the increase in EDSS score
from baseline in the combined analysis population, and this
relationship between BVL and worsening disability
strengthened with time during the 4 years analyzed. As
described earlier for this analysis, disability at baseline
correlated more strongly with baseline NBV than with
BVL on study, even though the strength of correlation
between disability worsening and BVL was seen to
increase over time. The strength of correlation with NBV at
baseline may be indicative of the fact that in these studies,
the patients enrolled, on average, 7–11 years after the
appearance of first MS symptoms; hence, NBV at baseline
effectively reflects BVL from the time of disease onset to
enrollment [45].
4.4 Clinical Relevance of BVL and Implications
for Fingolimod
A recent meta-analysis of 13 placebo-controlled studies
that included more than 13,500 patients with RMS (treated
with alemtuzumab, dimethyl fumarate, cladribine, fin-
golimod, glatiramer acetate, IFNb-1a IM, IFNb-1b, natal-
izumab, or teriflunomide) showed that over a 2-year period,
treatment effects on BVL and on T2 lesions correlated
independently with treatment effects on disability pro-
gression. Importantly, treatment effects on BVL and on T2
lesions in combination accounted for a greater proportion
of the effect on disability than was accounted for by each
parameter in isolation [18]. If T2 lesions are considered to
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provide a measure of inflammatory disease burden, this
result implies that in addition to those changes related
directly to inflammatory disease, global changes in BV
may capture other aspects of disease progression in MS,
such as neurodegeneration.
These effects seen at the group level are in accordance
with a more recent analysis at the patient level in FREE-
DOMS, which found the effects of fingolimod on BVL and
relapses to be independent of its effect on disability. The
analysis set out to examine whether the effect of fin-
golimod on disability progression was mediated by its
effect on lesions, relapses, or BVL. The effect on T2 lesion
count and on the number of relapses in year 1 of FREE-
DOMS accounted, respectively, for 46 and 60% of the
overall effect on 6-month confirmed disability progression
over 2 years, and the effect on reducing annual BVL
accounted for 23% of the overall effect in reducing dis-
ability. In a multivariate analysis, relapses and BVL pre-
dicted disability progression independently, but T2 lesion
count did not, and the effect of fingolimod on relapses and
BVL in combination accounted for 73% of the effect on
disability (Fig. 5). Taken together, these findings suggest
that, in RMS cohorts, fingolimod may reduce BVL via a
mechanism that is at least in part independent of any
Table 3 Summary of methodology used for examining correlates of BV and the associated clinical relevance [45]
Evaluation BV
parameter





Duration of MS since first
symptoms
Number of relapses during
the year before study
Number of relapses during










Pairwise Pearson (or Spearman) correlation: data presented with 95% CIs and
p values determined using Fisher z transformation
Statistical model selection process to identify the best baseline predictors of
NBV:
1. Forward model selection based on multiple regression models and AIC
was conducted separately for each study
2. The order of importance was ranked in each study, and ranks were then
averaged across studies to weight the studies equally. The best baseline
predictors were defined as those with the lowest mean ranks across studies.
Only candidate variables that were consistently selected in all studies were
considered for inclusion in the final model
3. The analysis was repeated, excluding MSFC as a candidate variable
4. A multiple linear regression model was used to investigate the combined
effect of more than one explanatory variable on NBV










Pairwise Pearson or Spearman correlation as above
Statistical model selection process as steps 1–3 above, then:
4. A final multiple regression model with treatment and the two best
predictors was then refitted to the data from each of the three studies to












Cumulative number of Gd-
enhancing lesions
T2 lesion volume




Pairwise Pearson or Spearman correlation: data were presented with 95% CIs
and p values determined using Fisher z transformation
AIC Akaike Information Criterion, BV brain volume, CI confidence interval, EDSS Expanded Disability Status Scale, Gd gadolinium, MS
multiple sclerosis, MSFC MS Functional Composite, NBV normalized brain volume, PBVC percentage brain volume change
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reduction directly attributable to its anti-inflammatory
activity [50].
This hypothesis is supported by a post hoc analysis of
the pooled FREEDOMS and FREEDOMS II populations,
in which the effects of fingolimod on BVL were examined
with and without adjustment for relapses and active MRI
lesions on study. At month 24 in the unadjusted analysis,
there was an absolute difference in BVL of 0.51% favoring
fingolimod over placebo, compared with an absolute dif-
ference of 0.27% in the analysis adjusted for relapses and
lesion activity. The ratio of these effect sizes implies that
about half of the reduction in BVL associated with fin-
golimod treatment occurs independently of its effect on
inflammatory disease in MS. This analysis was comple-
mented by an analysis which found that fingolimod
reduced BVL relative to placebo by 48.2% (p = 0.004) at
month 24 in the subgroup of patients in the pooled
FREEDOMS and FREEDOMS II population who had no
Gd? lesions at baseline and who had experienced neither
relapses nor new lesion activity on study. A treatment
effect on BVL in this group of patients implies that fin-
golimod is acting on pathologies affecting non-lesional
tissues in the brain or possibly on lesional tissue that is
clinically silent or radiologically inapparent [51].
4.5 Disease Activity and BVL
The correlation between BVL and disability progression,
the association between treatment effects to reduce BVL
and the slowing of disability progression, and the evidence
that such treatment effects may influence both inflammatory
and neurodegenerative pathologies in the brain in MS lend
weight to the notion that measurement of BVL might
become a useful part of routine patient follow-up. For
example, it could provide neurologists with information
about treatment response and subclinical disease progres-
sion between relapses, before worsening disability mani-
fests clinically. The effect of including BVL in a
combination assessment of disease activity has been
investigated in a population of patients pooled from the two
FREEDOMS trials [52]. A four-parameter measure of ‘no
evident disease activity’ (NEDA-4) assessed the presence of
relapses, T2 lesion activity, 6-month confirmed disability
progression, and annual BVL, and adopted a threshold rate
of 0.4% [52], below which annual BVL may be considered
to be in the normal range [8]. At 2 years, 19.7% of patients
receiving fingolimod attained NEDA-4 status, compared
with 5.3% of patients on placebo (odds ratio 4.41;
p\ 0.0001). Excluding assessment of BVL found that
31.0% of patients on fingolimod and 9.9% of patients on
placebo (odds ratio 4.07; p\ 0.0001) had no evidence of
disease activity, so inclusion of BVL certainly appeared to
improve the stringency of the combination measure. The
ultimate aim of applying such a combination measure in
clinical practice would be to establish that remission from
disease progression is complete; such an aspiration for
NEDA-4 will require validation in long-term studies [52].
While likely to provide information about rates of dis-
ease progression, assessment of BVL relies on waiting for
changes in BV (and therefore neurodegenerative damage)
to manifest. An alternative, cross-sectional approach has
been reported in which patients were categorized based on
whether their actual NBV was lower than, similar to, or
greater than a value estimated for them based on various
demographic and disease characteristics. Regression anal-
ysis of patient data from the two FREEDOMS trials that
accounted for age, disease duration, sex, disability status,
and T2 lesion volume was used to generate a formula to
estimate NBV on an individual basis. Patients categorized
as having low NBV had the highest risk of 3-month con-
firmed disability progression over 2 years (hazard ratio
1.75, relative to the high NBV group; p = 0.001) [53].
Based on this example from the two FREEDOMS trial
populations, the approach could be extended using data
from a broad range of patients with MS to produce a
generally applicable regression equation. This in turn could










Fig. 5 Relationships between individual outcomes and disability
progression in the FREEDOMS trial. Reproduced from Sormani et al.
[50]. Pies show the PTE of fingolimod on disability progression at
2 years accounted for by its effect on active T2 lesions at 1 year, on
relapses at 1 year, on PBVC at 2 years, and on relapses and PBVC
combined, both of which were determined to be independent
predictors of disability progression. PBVC percentage brain volume
change, PTE proportion of treatment effect
300 N. De Stefano et al.
5 Monitoring BVL in Clinical Practice
5.1 Guideline Recommendations
Despite the key role that MRI plays in the diagnosis and
monitoring of disease progression in MS, and in the
assessment of treatment efficacy, BVL assessment is
excluded from almost all national guidelines for the man-
agement of MS, and few guidelines even refer to it.
5.1.1 European Guideline Recommendations
In 2015, the second part of the Magnetic Resonance
Imaging in MS (MAGNIMS) consensus guidelines on the
use of MRI in MS was published. The guidelines make a
number of important recommendations for the use of MRI
in disease prognosis and monitoring, but only discuss
measurement of BV or BVL briefly and cautiously, noting
the problems of confounding factors and pseudoatrophy
affecting measurements [54].
5.1.2 Canadian Guideline Recommendations
In 2013, the Canadian Multiple Sclerosis Working Group
(CMSWG) published a set of recommendations for treat-
ment optimization in MS. Technical obstacles to assess-
ment of BV were noted, as was the lack of available
evidence that BVL signals a suboptimal response to treat-
ment that warrants treatment review [55]. However, there
is evidence that this position may be changing. In 2015, the
Canadian Expert Panel Recommendations for MRI Use in
MS Diagnosis and Monitoring guidelines made the rec-
ommendation ‘‘[to] include three-dimensional T1 pre-
contrast, diffusion-weighted imaging … in anticipation of
future automatic volumetric analysis for brain atrophy’’
[56].
Subsequent to the CMSWG guidelines, the Canadian
MRI Working Group published recommendations on the
evolving role of MRI assessments in MS treatment
optimization, focusing specifically on the standardiza-
tion of MRI use, acquisition, and reporting in patients
with RMS who are already on treatment. Qualitative
reporting of BV changes was recommended as part of
routine MRI assessment, and the guidelines also stated
that ‘‘In comparing scans, the radiologist … should
comment on whether there is evidence of significant
brain atrophy. The reporting of brain atrophy will usu-
ally be confined to two scans obtained at least one year
apart’’ [57].
Although assessment of BVL is not mandated, advo-
cating that MRI assessments of BV are conducted regularly
for retrospective assessment is an important development
in MS clinical practice. Adopting these techniques may
become more widespread in routine clinical care as our
understanding of the value of BVL assessment increases.
For example, a recent study found that non-responders to
IFNb could be identified with greater sensitivity if mea-
sures of BVL were added to known predictive factors [58].
5.2 Challenges to the Adoption of Routine BV
Assessment in Clinical Practice
Longitudinal assessment of BVL is not performed routinely
in clinical practice, and a number of challenges will need to
be overcome before estimation of BV can become routine
(Table 4). One example of such challenges is the possi-
bility that physiological variables may confound analysis
(e.g., level of hydration and inflammation-related volume
changes) [57], and another is the variation between dif-
ferent centers in the methods used for advanced quantita-
tive imaging [54, 57].
5.2.1 Issues with Algorithms Used for Estimating BV
and BVL
Cross-sectional algorithms such as SIENAX, Neu-
roQuant, and MSmetrixTM are used to estimate BV in
patients with MS [6, 14, 59, 60]. SIENAX is an automated
method used by several expert reading centers that mea-
sures BV from a single MRI scan normalized to a standard
skull [6]. NeuroQuant is US Food and Drug Administration
(FDA)-approved software that automatically segments and
measures volumes of brain structures using MRI images
obtained in routine clinical practice or in clinical trials
[59, 61]. Finally, MSmetrix is also an FDA-approved
automated technique that measures global and local brain
atrophy, as well as lesion load [60, 62]. Despite automa-
tion, none of these techniques provides accurate assess-
ments every time they are used, and each presents different
challenges when correcting measurement errors. A recent
comparative analysis of SIENAX with NeuroQuant and
MSMetrix in patients with RMS (n = 61) or clinically
isolated syndrome (n = 2) found that both NeuroQuant and
MSMetrix quantified whole BV with an accuracy compa-
rable with that yielded with SIENAX, suggesting that
either algorithm could be used for fully automated routine
cross-sectional BV estimation [62].
The SIENA algorithm was designed specifically for
longitudinal analyses and has an error rate of 0.15% when
determining longitudinal changes in BV [6]. In addition to
changes in BV, MSmetrix can also measure longitudinal
changes in white matter and lesion volume, which is useful
for monitoring disease progression [63]. Regional longi-
tudinal assessment of changes in ventricular cerebrospinal
fluid volumes can be made using NeuroSTREAM (Neu-
rological Software Tool for REliable Atrophy
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Measurement), a tool under development that compares
individual patient data with a normative database adjusted
for age, sex, disease duration, disability level, and MS
disease course [64].
Other recommendations that begin to address the chal-
lenges of conducting longitudinal MRI measurements of
BV include (i) acquisition of images using isotropic three-
dimensional pulse sequences with multiple image con-
trasts, to allow for more comprehensive analyses of lesion
load and atrophy across time points; (ii) use of robust
automated methods that have demonstrated precise BV
assessment in scan–rescan data; and (iii) creation of a
standardized dataset of benchmark results, to facilitate the
development, calibration and objective evaluation of the
image analysis methods that are used in MS [65].
5.2.2 Biological Factors that can Confound BV and BVL
Measurement
As mentioned earlier, it is known that hydration levels and
inflammation-related volume changes can affect BV, but
atrophy rates can also be affected by various other factors.
For example, significantly higher atrophy rates have been
associated with older age; higher glycated hemoglobin A
levels, body mass index, and alcohol intake; severe white
matter hyperintensity; and being a carrier of the APOE
epsilon4 gene [66]. They can also be confounded by factors
such as treatment-induced pseudoatrophy, smoking status,
and hydration level [67]. Treatment-induced pseudoatro-
phy merits particular attention. Anti-inflammatory drugs
used to treat MS have often been associated with a para-
doxical acceleration of BVL following therapy initiation;
this is termed pseudoatrophy [64, 68]. It may be
attributable to resolution of inflammatory edema, or to
other mechanisms that cause changes in the water content
of tissues, but to allow for this potentially confounding
effect, some studies have excluded the first 6 months of BV
measurement from analyses of BVL [11, 69]. Finally, a
recent analysis of over 3000 serial scans from 755 patients
with MS established that diurnal variations in BV occur,
with BV generally being greater in the morning than at
other times of day [70].
Table 4 Challenges to the adoption of BV assessment in routine clinical practice
Category Topic






Disease-related factors [11, 57, 64, 74–77] Fluid-level changes attributable to inflammation (edema)
Fluid-level changes attributable to resolution of inflammation
(treatment-related pseudoatrophy)





MRI-related factors [11, 57, 64, 65, 74, 76] Changes in acquisition protocols
Changes in scanner type and scanner upgrades




Patient repositioning in the scanner
Logistical factors [11, 57, 64, 65, 76] Reimbursement
Complexity of use (e.g. PACS integration)
Lack of normative data
Methods dependent on real-time data
Poor integration of some image formats
ApoE apolipoprotein E gene, BV brain volume, MRI magnetic resonance imaging, PACS Picture Archiving and Communication System
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5.2.3 BVL as a Biomarker for Regulatory Approval of MS
Therapies
In RMS, relapses, disability worsening, and MRI lesion
activity are the measures generally used to determine the
therapeutic efficacy of an MS drug in pivotal interventional
trials. However, these measures can overlook clinically
silent neurodegenerative disease progression. In contrast,
BVL measurement captures global changes in the brain, so
potentially provides a more sensitive assessment of disease
progression than these other measures. There are several
aspects to consider before adopting BVL as a biomarker for
regulatory approval of MS therapies. Some of these aspects
present obstacles but others have been addressed
successfully.
In terms of obstacles, there is currently little precedent
for the use of BVL as a primary study endpoint in RMS. It
was the primary endpoint in a phase II placebo-controlled
trial of riluzole and IFNb-1a IM in early MS [71], but to
date, BVL has not been the primary endpoint in a phase III
interventional trial. Also, as discussed earlier, there is a
lack of methodological standardization both for BVL
measurement and for data processing that allows for con-
founding factors. One further obstacle to overcome is
clinical adoption. If BVL was the primary measure of
therapeutic efficacy for MS therapies, more widespread
measurement of volumetric MRI within routine clinical
follow-up would be needed.
What is encouraging is that the clinical relevance and
the clinical definition of BVL as a biomarker in MS have
been investigated and established. The correlation
between BVL and disability in MS [45, 49–51], and the
association between treatment effects on BVL and on
disability [18], have been demonstrated in post hoc
analyses of several large study populations. Furthermore,
in terms of a clinical definition, analyses at the patient
level have defined a threshold rate of BVL that distin-
guishes normal from pathological BVL with good speci-
ficity and sensitivity [8].
6 Conclusions
There is comprehensive evidence from several large phase
III studies that fingolimod significantly reduces the extent
and rate of BVL in patients with RMS. In these studies,
fingolimod reduced annual BVL by approximately one-
third relative to that observed in patients receiving placebo
or IFNb-1a IM, and this reduced rate was sustained in
individuals treated continuously with fingolimod in the
study extensions. Subgroup analyses have shown that the
ability of fingolimod to reduce BVL is independent of
treatment history, baseline disability level, and
inflammatory lesion activity both at baseline and on study.
Data from post hoc analyses of fingolimod phase III studies
have identified a number of predictors of baseline NBV and
of changes in BV during treatment, including age, dis-
ability level, disease burden, and inflammatory lesion
activity; baseline T2 lesion and Gd? lesion burdens at
baseline were particularly strong predictors of BVL in the
subsequent 2 years. Understanding changes in BV that
occur during the disease course and in response to existing
disease-modifying therapies may help to provide neurolo-
gists with new insights into their patients’ prognoses, and
to guide them when reviewing treatment. Several obstacles
to routine MRI monitoring of BV could be overcome in the
near future, but its increased adoption in the wider neuro-
logical community is almost certainly reliant on raising
awareness of the potential benefits afforded to patients by
routine BV assessment.
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